Volanesorsen

Drug Profile

Volanesorsen

Alternative Names: IONIS-APOCIIIRx; ISIS-304801; ISIS-APOCIII; ISIS-APOCIII-Rx

Latest Information Update: 23 Mar 2017

Price : $50

At a glance

  • Originator Isis Pharmaceuticals
  • Developer Akcea Therapeutics; Ionis Pharmaceuticals
  • Class Antihyperlipidaemics; Antisense oligonucleotides; Antisense RNA
  • Mechanism of Action Apolipoprotein C-III inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hyperlipoproteinaemias; Lipodystrophy
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Hyperlipoproteinaemia type I; Hypertriglyceridaemia; Lipodystrophy
  • Preclinical Cardiovascular disorders

Most Recent Events

  • 06 Mar 2017 Ionis Pharmaceuticals and Akcea Therapeutics plan to make regulatory submissions to US, Europe and Canada in Hyperlipoproteinaemia type I in 2017
  • 06 Mar 2017 Efficacy and adverse events data from the phase III APPROACH trial in Hyperlipoproteinaemia released by Ionis Pharmaceuticals and Akcea Therapeutics
  • 06 Mar 2017 Pooled adverse events data from the phase III APPROACH trial in Hyperlipoproteinaemia type I and the phase III COMPASS trial for Hypertriglyceridaemia released by Ionis Pharmaceuticals and Akcea Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top